Cargando…

Efficacy and Safety of Risankizumab for the Treatment of Hidradenitis Suppurativa: A Phase 2, Randomized, Placebo-Controlled Trial

INTRODUCTION: Hidradenitis suppurativa (HS) is a chronic, immune-mediated skin condition characterized by inflammatory lesions that can cause pain, impaired physical activity, and reduced quality of life. This study evaluated the efficacy and safety of risankizumab, a humanized immunoglobulin G1 mon...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kimball, Alexa B., Prens, Errol P., Passeron, Thierry, Maverakis, Emanual, Turchin, Irina, Beeck, Stefan, Drogaris, Leonidas, Geng, Ziqian, Zhan, Tianyu, Messina, Izabella, Bechara, Falk G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9997424/ https://www.ncbi.nlm.nih.gov/pubmed/36892753 http://dx.doi.org/10.1007/s13555-023-00913-3

Ejemplares similares

Evidence-based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativa
por: Gulliver, Wayne, et al.
Publicado: (2016)

Efficacy and Safety of Risankizumab in Hidradenitis Suppurativa: A Case Series
por: REPETTO, Federica, et al.
Publicado: (2022)

Efficacy and Safety of Adalimumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa: The SHARPS Randomized Clinical Trial
por: Bechara, Falk G., et al.
Publicado: (2021)

IL‐17A is a pertinent therapeutic target for moderate‐to‐severe hidradenitis suppurativa: Combined results from a pre‐clinical and phase II proof‐of‐concept study
por: Kimball, Alexa B., et al.
Publicado: (2022)

Baseline Characteristics from UNITE: An Observational, International, Multicentre Registry to Evaluate Hidradenitis Suppurativa (Acne Inversa) in Clinical Practice
por: Prens, Errol P., et al.
Publicado: (2020)

Assessing Pruritus in Hidradenitis Suppurativa: A Cross-Sectional Study
por: Vossen, Allard R. J. V., et al.
Publicado: (2017)

TNF-α inhibitors in the treatment of hidradenitis suppurativa
por: Savage, Kevin T., et al.
Publicado: (2019)

Clinical Implementation of Biologics and Small Molecules in the Treatment of Hidradenitis Suppurativa
por: Aarts, Pim, et al.
Publicado: (2021)

Response to: Remission of hidradenitis suppurativa after bariatric surgery
por: Golbari, Nicole Mona, et al.
Publicado: (2018)

Hidradenitis Suppurativa: A Systematic Review Integrating Inflammatory Pathways Into a Cohesive Pathogenic Model
por: Vossen, Allard R. J. V., et al.
Publicado: (2018)

Guselkumab, Risankizumab, and Tildrakizumab in the Management of Hidradenitis Suppurativa: A Review of Existing Trials and Real-Life Data
por: Martora, Fabrizio, et al.
Publicado: (2023)

Contribution of plasma cells and B cells to hidradenitis suppurativa pathogenesis
por: Gudjonsson, Johann E., et al.
Publicado: (2020)

New insights in hidradenitis suppurativa from a population‐based Dutch cohort: prevalence, smoking behaviour, socioeconomic status and comorbidities
por: Prens, Lisette M., et al.
Publicado: (2022)

The Role of Hormones in Hidradenitis Suppurativa: A Systematic Review
por: Abu Rached, Nessr, et al.
Publicado: (2022)

Novel cytokine and chemokine markers of hidradenitis suppurativa reflect chronic inflammation and itch
por: Vossen, Allard R. J. V., et al.
Publicado: (2018)

Current Medical and Surgical Treatment of Hidradenitis Suppurativa—A Comprehensive Review
por: Ocker, Lennart, et al.
Publicado: (2022)

Risankizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
por: Tyring, Stephen K., et al.
Publicado: (2023)

Treatment of hidradenitis suppurativa resolves associated hematologic abnormalities
por: Morss-Walton, Peyton C., et al.
Publicado: (2022)

Validity and Reliability of Two Digital Wound Measurement Tools after Surgery in Patients with Hidradenitis Suppurativa
por: Aarts, Pim, et al.
Publicado: (2023)

Comorbidity screening in hidradenitis suppurativa: Evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa Foundations
por: Garg, Amit, et al.
Publicado: (2022)

Primary alterations during the development of hidradenitis suppurativa
por: Dajnoki, Z., et al.
Publicado: (2021)

Adalimumab and infliximab survival in patients with hidradenitis suppurativa: a daily practice cohort study
por: Prens, L.M., et al.
Publicado: (2021)

High and discordant prevalences of clinical and sonographic enthesitis in patients with hidradenitis suppurativa
por: van Straalen, K.R., et al.
Publicado: (2020)

33892 Telehealth use at a specialty hidradenitis suppurativa clinic during the COVID-19 pandemic
por: Kim, Diana S., et al.
Publicado: (2022)

Tofacitinib shows benefit in conjunction with other therapies in recalcitrant hidradenitis suppurativa patients
por: Savage, Kevin T., et al.
Publicado: (2020)

Methotrexate shows benefit in a subset of patients with severe hidradenitis suppurativa
por: Savage, Kevin T., et al.
Publicado: (2020)

Hidradenitis suppurativa in AIDS
por: Khambhati, Ravi, et al.
Publicado: (2010)

Hidradenitis suppurativa and intimacy
por: Jemec, G.
Publicado: (2018)

Clindamycin-Benzoyl Peroxide Gel Compared with Clindamycin Lotion for Hidradenitis Suppurativa: A Randomized Controlled Assessor-Blinded Intra-Patient Pilot Study
por: Aarts, Pim, et al.
Publicado: (2023)

Coexistence of Hidradenitis Suppurativa and Steatocystoma Multiplex: Is It a New Variant of Hidradenitis Suppurativa?
por: Fletcher, Joshua, et al.
Publicado: (2021)

Erythrocyte sedimentation rate, rather than C-reactive protein, may be the preferred biomarker for hidradenitis suppurativa
por: Gibson, Ruby S., et al.
Publicado: (2022)

Screening for Diabetes Mellitus in Patients with Hidradenitis Suppurativa—A Monocentric Study in Germany
por: Abu Rached, Nessr, et al.
Publicado: (2023)

HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo‐controlled portion of a phase 2 adalimumab study
por: Kimball, A.B., et al.
Publicado: (2015)

Adalimumab medium‐term dosing strategy in moderate‐to‐severe hidradenitis suppurativa: integrated results from the phase III randomized placebo‐controlled PIONEER trials
por: Jemec, G.B.E., et al.
Publicado: (2019)

Noninvasive assessment of cytokine and antimicrobial peptide levels in hidradenitis suppurativa using transdermal analysis patches
por: Ardon, C.B., et al.
Publicado: (2020)

Travel burden on patients at a subspecialty hidradenitis suppurativa clinic: a single-center retrospective study
por: Kim, Diana S., et al.
Publicado: (2022)

Surgical Management of Hidradenitis Suppurativa
por: Menderes, Adnan, et al.
Publicado: (2010)

Hidradenitis Suppurativa: Inside and Out
por: Patil, Sharmila, et al.
Publicado: (2018)

Multimodal management of hidradenitis suppurativa
por: Jemec, Gregor B.E.
Publicado: (2020)

Leflunomide-Induced Hidradenitis Suppurativa
por: Machan, Achraf, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_093f1ui2q0hp5qflq2b6og6l7e